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Abstract
To focus attention, our brain has to “gate” or block irrelevant sensory information that
could lead to brain overload. This is done by way of a neuronal pre-attentive
mechanism termed sensorimotor gating (SG). Therefore, deficits in the SG mechanism
prevent patients from focusing attention. SG deficits have been observed in patients
suffering from various neurological disorders, and it is a hallmark of schizophrenia.
Previous work has identified key brain areas, such as the pedunculopontine tegmental
nucleus (PPTg), that send inputs to the brainstem to regulate SG. However, there is still
a knowledge gap concerning what cell types are involved and what other brain areas
could potentially contribute to SG. Our objective in this study is to further identify the
cell types located in the PPTg that contribute to SG. The caudal pontine reticular
nucleus (PnC) is the brainstem area at the center of the SG circuitry. It has been long
known that the PPTg contains cholinergic, glutamatergic and GABAergic neurons and
sends direct inputs to the PnC, modulating SG. Recently, the contribution of cholinergic
neurons to SG has been shown to be minimal. Therefore, it is not known whether other
PPTg neurons project to the PnC and whether they contribute to SG. We Investigated
the role of the PPTg glutamatergic inputs onto the PnC in the context of SG, which had
not been demonstrated before.
To test our hypothesis, we used neuronal dyes to label cellular pathways,
immunohistochemistry to reveal cellular neurochemistry and in vivo optogenetic to
functionally study the contribution of the PPTg-PnC glutamatergic connection to SG.
Our data show for the first time that there is a direct glutamatergic connection between
the PPTg and the PnC, and that it does contribute to SG in vivo.
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Chapter I: Introduction
I.1. Sensorimotor Gating
Sensorimotor gating (SG) is a neuronal mechanism that helps us to filter out
irrelevant sensory information before we consciously focus attention (Logan, 1992;
Swerdlow, 1996; Swerdlow 1999). Deficits in SG have been reported in people suffering
from various neurological disorders such as schizophrenia, obsessive compulsive
disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), Huntington’s disease
(HD), Tourette’s syndrome, post-traumatic stress disorder (PTSD), and autism spectrum
disorders (ASD) (Geyer and Braff, 1987; Swerdlow et al., 1993; Swerdlow and Geyer,
1998; Swerdlow et al., 2001; Kohl et al., 2013; Sinclair et al., 2017). This pre-attentive
mechanism deficit is a true problem since there is no known cure for it, meaning that
people’s social insertion and cognitive performance will be impaired for an undefined
amount of time. SG deficits are a hallmark of schizophrenia, which affects 21 million
people worldwide currently, according to the World Health Organization. Since SG
deficits are a burden for millions of people, efforts must be done in order to better
understand the neuronal pathways and elements that underpin SG.
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I.2. The Acoustic Startle Response and Prepulse inhibition
Both in laboratory and clinical settings, SG can be measured by the prepulse
inhibition (PPI) of the startle reflex task (Ison and Hammond, 1971; Geyer and Braff,
1982; Koch et al., 1993; Swerdlow et al., 2001). As an operational measure of SG, PPI can
be measured in both humans and animal models (Graham, 1975; Braff et al., 1978;
Swerdlow et al., 2001; Bosch and Schmid, 2006). As seen in Figure 1.1, The PPI task is
performed by presenting a non-startling sensory stimulus (also termed “pre-pulse”)
prior to a startling sensory stimulus (“pulse”), to a subject. The non-startling stimulus
can diminish the startle response elicited by the startling stimulus. The diminished
startle response is what is known as prepulse inhibition of the startle response. PPI can
be measured using different sensory modalities (Fendt et al., 2001), and since it is an
operational measure of SG, it is impaired in people suffering from schizophrenia. Thus,
in disease states, a reduction in PPI is observed and results in a significant startle
response even when a non-startling stimulus precedes the startling stimulus. Since PPI
can be

measured across species, many animal models of
disease have been used
to study SG deficits.
Despite this, there are
still gaps in the
understanding of the
SG neuronal circuitry and efforts are still

Figure 1.1. The Prepulse inhibition of the startle reflex task. The Top
panel shows the startle reflex when only the startling stimulus is being
presented, and the Bottom pane shows the prepulse before the startling
pulse and showing a % reduction in PPI.
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needed towards
developing

therapeutic strategies for pre-attentive deficits.
The previous PPI behavioral studies mostly employed tactile or auditory sensory
stimuli. Previous published work using acoustic sensory stimulations allowed us to
better understand the neural circuitry mediating SG. The acoustic startle reflex (ASR) is
elicited when a loud startling sound enters the ear, stimulates the hair cells in the
cochlea activating the cochlear nuclei. The cochlear nuclei then innervate the giant
glutamatergic neurons in the brainstem caudal pontine reticular nucleus (PnC) which
then activate the spinal cord, cranial, and facial motor neurons causing a startling
response as seen in Figure 1.2 (Lingenhöhl and Friauf, 1994; Swerdlow et al., 2001;
Fendt et al., 2001; Bosch and Schmid, 2006). This pathway is short; it only takes a few
milliseconds for the stimulus to travel from cochlear sensory receptors to the startling
response. During PPI, a non-startling stimulus is presented a few milliseconds prior to
the startling stimulus. This non-startling stimulus will activate different brain regions
before ultimately converging to the startling stimulus pathway. That is, a non-startling
stimulus will first activate the cochlear nuclei, but then, the inferior and superior
colliculi will be activated which will lead to the activation of the pedunculopontine
tegmental nucleus (PPTg). Once activated, the PPTg was thought to be responsible for
the inhibition of the PnC giant glutamatergic neurons as seen in Figure 1.2 (Davis et al.,
1982; Swerdlow et al., 2001; Fendt et al., 2001). Once inhibited by the PPTg, the
subsequent activation of PnC by a startling stimulus leads to a smaller startle reaction
compared to the startle response induced by the pulse presented alone (Koch et al.,
1993). Even though much is known about the brain regions underlying PPI, there is a
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large knowledge gap in regards of the chemical nature of the anatomical connection
between the PnC and the PPTg, which is thought to be at the heart of SG.
I.3. The PPTg-PnC connection and neurotransmitters involved
The PPTg is a major cholinergic center in the lower brain (Saper and Loewy,
1982; Armstrong et al., 1983; Rye et al., 1987), but also contains glutamatergic (Clements
and Grant, 1990; Koch et al., 1993; Wang and Morales, 2009) and GABAergic neurons
(Swerdlow et al., 2001; Fendt et al., 2001; Wang and Morales, 2009; Kroeger et al., 2017;
Mena-Segovia and Bolam, 2017). The PPTg has been mainly studied due to his
involvement in arousal and modulation of sleep/wale cycles, sensorimotor gating, but

Figure 1.2. The Acoustic Startle Pathway, the PPI pathway, and the areas that modulate and regulate PPI.
The Top of the figure shows the brain regions that are activated by the prepulse who mediate PPI. The regions
send their inputs to the PPTg/LDTg or the substantia nigra pars compacta (SNR) which send cholinergic and
GABAergic projections to the PnC, respectively. The Bottom of the figure shows the pathways that the ASR
follows through different startling stimuli. If a prepulse reaches the PPTg before a startling stimulus had the
time to reach the PnC, then the prepulse-induced inhibition of the PPTg will lead to a decreased startle
response. (Fendt, et al., 2001)
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not much of the PPTg is studied in its involvement on motor systems. Some studies
have shown that the PPTg sends has direct connections with the mesencephalic
locomotor region (MLR), first described by Shik et al., (1966) and following studies
showed that activation of the PPTg in decerebrate cats elicited movement (Garcia-Rill et
al., 1987). Several studies done in rats by Bosch and Schmid have been performed to
understand how the PPTg inhibits the PnC. Initially, these studies suggested that the
cholinergic neurons are the only neurons responsible of the inhibition of the startle
response by activating muscarinic receptors (M2 and M4) on PnC neurons (Bosch and
Schmid, 2006, 2008). In fact, during the PPI protocol performed on an in vitro slice
preparation, the activation of PPTg fibers led to the inhibition of PnC neuronal activity.
Interestingly, under these in vitro conditions, PPI only occurred when the prepulse and
the pulse were separated by the specific inter-stimulus intervals (ISIs) of 300 and 1000
ms. To confirm the contribution of the muscarinic receptors to PPI induced by the PPTg
stimulation, the muscarinic receptor antagonist scopolamine was added to the PnC slice
preparation. Surprisingly, scopolamine abolished the in vitro PPI phenomenon only at
the 1000 ms ISI, but not at the 300 ms ISI inhibition. From these results, it was thought
that different neurotransmitters and receptors might contribute to PPI, depending on
the ISI separating the pulse from the prepulse (Bosch and Schmid, 2008). Another
argument supporting this hypothesis was the fact that disrupting the cholinergic
projections linking the PPTg to the PnC only decreased PPI, without abolishing it. The
results from these earlier studies made us suggest that there must be other PPTg
neurons (and neurotransmitters) and/or other brain areas contributing to the inhibition
of the PnC during PPI.
Recently, elegant studies further demonstrated the contribution of other
neurotransmitters to PPI, such as glutamate. First, it was shown that a non-selective
5

damage to all the neuronal types within the PPTg reduces PPI. In contrast, the selective
disruption of the PPTg cholinergic neurons did not affect PPI (MacLaren et al., 2014).
Then, in a gene sequencing study, it was found that the zebrafish Gsx1 gene, which is
essential for proper PPI, is present in PPTg glutamatergic neurons in mice. Such studies
demonstrated that the neurons expressing the Gsx1 gene are equivalent to the PPTg
glutamatergic neurons in mice, and that they synapse onto the zebrafish Mauthner
neurons, which are equivalent to the PnC giant glutamatergic neurons (Bergeron et al.,
2015). This study used a simple animal model to suggest a cross-species occurrence
where a PPTg-PnC glutamatergic connection that is involved in PPI occurs. Other
studies showed that the activation of group III metabotropic glutamate receptors in the
PnC in vivo and in vitro with -AP4 strongly inhibits the giant glutamatergic neurons
L

(Schmid et al., 2010). The glutamatergic contribution to PPI was shown to come from
the medial pre-frontal cortex (mPFC) (Valsamis et al., 2014). In addition to glutamate,
the neurotransmitter GABA was also suggested to play a role during PPI. A rodent
study showed a significant GABAergic contribution to PPI at the level of the PnC by
applying different GABA receptor antagonists. Indeed, following bicuculline in vivo
injection, a decrease of PPI was observed at different ISIs (Yeomans et al., 2010).
Furthermore, many other studies have been done to identify other brain areas that have
a regulatory influence in PPI (Davis and Gendelman, 1977; Fendt et al., 2001). Such
studies have demonstrated that areas such as the PFC, the hippocampus (HPC), the
basolateral amygdala (BLA), and the nucleus accumbens (NAC) among others, are
areas that modulate PPI as seen in Figure 2 (Swerdlow et al., 2001; Fendt et al., 2001;
Miller et al., 2010; Kohl et al., 2013). The prefrontal cortex has shown to send
glutamatergic inputs to the PnC involved in PPI that have been studied in rats. The
study reports performing NMDAR antagonist injections in the PnC, and the disrupted
6

PPI was reversed with NMDAR agonist injections in the mPFC in vitro (Valsamis et al.,
2014).
While no direct anatomical connection has been described between the HPC and
the PnC, it has been shown that HPC is a modulator of PPI via different
neurotransmitters. Studies performed in rats showed the cholinergic receptor agonist
carbachol into the HPC and it affected PPI (Caine et al., 1991), in addition to showing a
glutamatergic component where NMDAR agonists applications in the vHPC inhibited
PPI (Wan et al., 1997). It has been known that the Amygdala is involved in modulating
PPI, and emerging research is showing a direct anatomical connection between the
basolateral amygdala (BLA) and the PnC (preliminary data). The modulation shown
has been described by lesion studies in rats with quinolinic acid in the BLA showing an
inhibited PPI. In addition, glutamatergic, dopaminergic and GABAergic components
from the BLA have been described by applying GABA receptor antagonist picrotoxin
a

and NDMAR antagonists dizocilpine into the BLA and inhibiting PPI, with a reversal
effect seen with a systemic injection of the dopamine antagonist haloperidol (Fendt et
al., 2001).
I.4. Why should we study the PPTg-PnC glutamatergic pathway?
Even though it is clear that more research efforts are needed to understand the
contribution from all the previously mentioned areas into PPI, the focus of my project is
to understand how the PPTg inhibits the PnC and to identify if glutamatergic neurons
from the PPTg might play a role in the inhibition of the PnC during PPI. The PPTg was
first described in humans in 1909 (Jacobsohn, 1909; Rye et al., 1987) and even though
much is known about it, there are currently no studies that have focused on the function
of the glutamatergic PPTg neurons in the context of SG. The PPTg forms part of the
7

extrapyramidal motor system (Saper and Loewy, 1982) and plays a key role in the
modulation of arousal and behavioral states in higher brain centers (Fendt et al., 2001;
Eban-Rothschild et al., 2016; Kroeger et al., 2017; Mena-Segovia and Bolam, 2017). The
PPTg contributes to the modulation of PPI of auditory and tactile sensory modalities.
As mentioned before, damages to the PPTg cause PPI disruptions, and patients with
schizophrenia have been found to have an increased number of PPTg cholinergic
neurons in humans (Karson et al., 1991). Furthermore, emerging research is suggesting
that the cholinergic neurons from the PPTg projecting to the PnC might not contribute
to PPI at all (Maclaren et al., 2014; Valsamis et al., 2014). As mentioned above, the PPTg
contains several neuronal subtypes (Wang and Morales 2009) and, from tracing studies,
it was shown that the different PPTg neuronal subpopulations likely target similar sites.
Therefore, we have hypothesized that excitatory glutamatergic neurons from the
PPTg might project to the PnC and contribute to PPI by activating, among other PnC
glycinergic interneurons. We could then speculate that once activated, these PnC
glycinergic interneurons could inhibit the PnC giant glutamatergic neurons and reduce
startle in vivo. If such PPTg-PnC glutamatergic connection is present and contributes to
PPI, a new way to study SG could emerge and potentially lead the way to the
development of therapeutic interventions to treat diseases associated with SG deficits.
I.5. Specific Aims
The proposed Specific Aims and experiments were designed to further
investigate the glutamatergic connection between the PPTg and the PnC using WT
mice:
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I.5.1. Specific Aim 1
To characterize the glutamatergic connection between the PPTg and the PnC.
Here, the goal was to identify and precisely locate the PPTg non-cholinergic (likely
glutamatergic) cell bodies in the caudal portion of the PPTg that sends projections to the
PnC. To do so, I injected a retrograde neuronal tracer and a retrograde virus into the
PnC and immuno-labelled the traced cell bodies within the PPTg. I also labeled and
visualized the PPTg neuronal fibers terminating within the PnC.
I.5.2. Specific Aim 2
To establish how PPTg-PnC glutamatergic synapses underpin SG in vivo.
Here, using a cannula-guided fiber optic in mice injected with inhibitory opsins, I
performed the prepulse inhibition (PPI) task in vivo. In some trials, I photo-silenced the
PPTg-PnC glutamatergic connection already identified in Aim1. Following the
behavioral testing, the brain was extracted and analyzed using immunohistochemistry
assays to double-label the targeted neurons and confirm the extent of the viral injection
and cannula placement.

9

Chapter II: Experimental Approach
II.1. Specific Aim 1 Experiments
Specific aim 1: To characterize the glutamatergic connection between the PPTg
and the PnC.

Experiment 1.1: I injected the retrograde neuronal tracer Fluorogold (FG) or the
adeno-associated retrograde viral particles driving the expression of the tdTomato
protein under the control of the CAG promoter (AAVrg-CAG-tdTomato) into the PnC,
where the PPTg axon terminals are present and take up the tracer molecules or virus
and back-fill the cell bodies within the PPTg. The labeling strategy can be seen in Figure
2.1.

Experiment 1.2: In a subset of mice, I injected either the tracer cholera toxin subunit B (CTB) (can be used both as an antero-and retrograde tracer) or the adenoassociated viral particles driving the expression of the mCherry protein under the
control of the CaMKIIa promoter (AAV-DJ-CaMKIIa-mCherry) into the PPTg. Because
these tracers travel in an anterograde fashion, they should label the PPTg neuronal cell
bodies, and also the extent of the axonal fibers/terminals expressing mCherry within
the PnC. The labeling strategy can be seen in Figure 2.1.

Experiment 1.3: I performed immunohistochemistry on the extracted brain tissue
cut into thin sections. More precisely, I treated these sections with the antibodies of the
proteins that we wished to target (described in more details below) to double-label the
cell bodies that were already made fluorescent by the neuronal tracers injected.

10

II.1.1. Objective and Overview
Neuronal labeling studies in rats previously identified a direct anatomical
connection between the PPTg cholinergic fibers and the PnC (Koch et al., 1993), and
such connection was initially thought to be the central contributor of sensorimotor
gating. Subsequent rodent in vitro studies demonstrated that this connection provides
an inhibitory influence on PnC neurons, but that other neurotransmitter systems also
contribute to PPI (Bosch and Schmid 2006; Bosch and Schmid 2008; Schmid et al., 2010;
Yeomans et al., 2010; Valsamis et al., 2014). Importantly, in situ hybridization and
immunohistochemical analyses provided evidence for the presence of glutamatergic
neurons within the PPTg (Clements and Grant, 1990; Wang and Morales, 2009).
Although PPTg glutamatergic neurons have also been shown to encode locomotor state
and speed (as a puitative part of the mesencephalic locomotor region), their function
has mainly been studied in the context of arousal (Roseberry et al., 2016; Kroeger et al.,
2017; Mena-Segovia and Bolam, 2017). Therefore, whether the PPTg glutamatergic
neurons are anatomically connected to the PnC and contribute to PPI is still unknown.

11

The objective of Specific Aim 1 was to identify and characterize a PPTg-PnC
glutamatergic connection. I first injected retrograde and anterograde neuronal
tracers/viral particles in the PnC and PPTg, respectively, and analyzed the fluorescence
of fibers and cell bodies in both regions as seen in Figure 2.1. Secondly, I used
immunohistochemistry to identify the chemical nature of the labeled neurons. The data
generated from experiments in Specific Aim 1 was needed to allow me to pursue my
second Aim, consisting of evaluating the functional contribution of this connection to
PPI in vivo. Such
anatomical
connection provides
information and can
fill a gap in the
understanding of the
modulation of PPI
and sensorimotor
gating by the PPTg.
Moreover, this

Figure 2.1. Neuronal labeling strategy. The injection sites of each neuronal
tracer used and the targeted regions, including the tracing direction are seen
in the scheme. This is the technique that was used for Specific Aim 1.

knowledge can potentially give us an understanding of this faulty mechanism
characterized in people with neurological disorders.
II.1.2. Materials and Methods
Animals: Adult C57CBL/6 male mice aged between 1-2 months (Jackson
Laboratories) housed in the University of Texas at El Paso (UTEP) vivarium with
controlled temperatures and a 12-hour light / dark cycle have been used for these
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experiments. All protocols were conducted in compliance of the UTEP Institutional
Animal Care and Use Committee (IACUC).
Surgery / neuronal tracer injections: All injections were done with a pressure
micro-injector (Quintessential Stereotaxic injector, Stoelting Co., IL). For the retrograde
labeling experiments, mice were injected unilaterally with 0.1 µL of the tracer
Fluorogold (FG; 2% in 9% Saline, Fluorochrome, Denver, CO) or the retrograde virus
AAVrg-CAG-tdTomato (Addgene viral prep # 59462-AAVrg) using pulled glass
micropipettes targeted at the PnC with the following stereotaxic coordinates relative to
Bregma: AP: -5.34 mm, ML: +7.0 mm, DV: -5.35 mm (Paxino’s and Franklin, 2004). For
the anterograde labeling experiments, mice were injected unilaterally with either 0.3 µL
total volume (2 injections of 0.15 µL each) of the Cholera Toxin Subunit B (CTB;
dilution: 0.5 µg/µL, Millipore) tracer or the AAV-DJ-CaMKIIa-mCherry viral particles
using pulled glass micropipettes targeted at the PPTg: coordinates are: #1 AP: -4.84
mm, ML: +1.3 mm, DV: -3.75; and #2 AP: -4.84 mm, ML: +1.3 mm, DV: -3.5mm. The
mice were anesthetized with 1.5% isoflurane (Vedco, Saint Joseph, Missouri) via
inhalation through a nose cone attached to the stereotaxic platform head holder for the
entire duration of the surgery. A seven days recovery period allowed maximum
transport of FG and CTB and a four week-period was used for the viral particles
proliferation. The mice were then anesthetized with isoflurane and exsanguinated by
transcardial perfusion with about 200 mL 9.0% saline solution followed by chilled 4.0%
paraformaldehyde (PFA) solution in phosphate buffered saline (PBS). After the
perfusion, the animals were decapitated and the brains were extracted and harvested by
post-fixing it in 30% sucrose in PFA for 12-18 hr. The brains were drained of excess
sucrose, and frozen in super cooled hexanes and stored at -80°C. Then, the brains were
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sectioned on a Leica CM3050 S Cryostat (Leica, Wetzlar, Germany). The sections were
cut into five 1-in-5 series throughout the extent of the PnC and PPTg at a thickness of 30
µm in the coronal plane of section in order to survey the whole area in which the PPTg
and PnC areas are present, since the areas are in a short distance from one another.
Sections were stored in cryoprotectant solution (50% 0.05 M phosphate buffer, 3-&
ethylene glycol, 20% glycerol) at -20°C until plated for visualization.
Histological Analyses: The viral constructs contained the reporter gene
mCherry, eYFP or tdTomato which are translated into fluorescent proteins. However,
using immunohistochemistry, I enhanced these protein's fluorescence for optimal
visualization/labelling. The brain sections that contained CTB had their fluorescence
enhanced since the tracer works stronger as a retrograde tracer and weaker as an
anterograde one. Additional antibodies were used to double-label the cells expressing
the dyes and reveal their identities. Appendix 2 lists the primary and secondary
antibodies, and the reagents used to enhance fluorescence. Fluorogold is not considered
in the table since it already expresses fluorescent properties and does not require
antibodies for visualization. The brain sections were rinsed off the cryoprotectant
solution for 5 times for 5 minutes each using Tris-buffered saline (TBS; pH 7.4 at room
temperature) and incubated in Blocking solution (NDS) (2% normal donkey serum;
EMD-Millipore, Billerica, MA; catalog #S30-100ML; lot NG1827420 and 0.1% Triton X100; Sigma-Aldrich, St. Louis, MO; catalog #T8532 in TBS) for 2-3 hr at room
temperature. The brain slices were collected and separated into two groups depending
on whether they contained the PPTg or the PnC. The PPTg sections were treated with
the antibody against Choline Acetyltransferase (ChAT) since until now, labeling PPTg
Cholinergic neurons with such antibody still constitutes the best way to delineate its
borders. The PnC sections were treated with the antibody against the Vesicular
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Glutamate Transporter type 2 (VGluT2) in an attempt to label and visualize excitatory
synapses. The antibodies used were dissolved to their working dilutions within the
blocking solution (NDS). Slices were incubated in combination of the primary
antibodies for 3 Days at 4°C. The slices were then washed off the primary antibody in
TBS for 5 times for 5 minutes each and incubated in combinations of secondary
antibodies for 6-8 hrs at room temperature, then rinsed again. The trays with the tissue
were covered under aluminum foil to prevent photo-bleaching during the antibody
treatment. The slices were then mounted on super frost slices, air-dried and cover
slipped. Nissl staining was performed on one of the tissue series to parcellate the nuclei
in the areas of interest. Cells in the slices were demyelinated and then rehydrated and
incubated in Thionin (Sigma-Aldrich, St. Louis, MO) solution and differentiated in 0.4%
glacial acetic acid in deionized water, then dehydrated and cleared with xylenes, before
being cover slipped with DPX (VWR, Radnor, PA catalog #360294H)
Microscopy: The slides were examined under the Zeiss Observer.Z1 equipped
with needed filter sets for Alexa 488, UV (for FG), and Texas Red. Sections were further
analyzed using the Keyence BZ-X710 All-in-one Fluorescence Microscope (Keyence, Inc.
Elmwood Park, NJ) with filter sets of DAPI, Alexa 488, Texas Red/Cy3, and UV (for FG)
to visualize the fluorescence from the injected dyes and the secondary antibodies in the
tissue.
II.2. Specific Aim 2 Experiments
Specific aim 2: To Establish how PPTg-PnC glutamatergic synapses underpin SG

in vivo.
Experiment 2.1: An optogenetic approach was used to selectively infect the
excitatory neurons of the PPTg by injecting the AAVDJ-CaMKIIα-eArch 3.0-eYFP
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(Archaerhodopsin, proton pump, sensitive to green light) or AAVDJ-CaMKIIαeNpHR2.0- eYFP (Halorhodopsin, chloride pump, sensitive to orange/yellow light)
(Yizhar et al., 2011) viral particles into the PPTg. The excitatory glutamatergic
projections from the PPTg were photo-inhibited within the PnC using green or
orange/yellow light, depending on the virus injected, while performing PPI in vivo.
Both types of opsins were used to further confirm the behavioral results, and as their
activation should yield similar outcomes.

Experiment 2.2: At the end of the behavioral testing sessions, the brain was
extracted, sectioned and analyzed through immunohistochemical assays. Since the viral
construct contained a reporter gene encoding a fluorescent protein, the additional
immunohistochemical experiments allowed me to double-label the neurons that were
infected by the viral particles and verify the chemical identity of such neurons. In
addition, the brain sections of the animals used for the behavioral experiments allowed
me to confirm the correct placement and implantation of the optic fiber/cannula.
II.2.1. Objective and Overview
Previous in vivo and in vitro rodent studies demonstrated that the PPTg is one of
the major modulators of PPI, though its cholinergic input to the PnC (Koch et al.,1993;
Bosch and Schmid, 2006; Bosch and Schmid, 2008). Interestingly, the PPTg cholinergic
neurons inhibited the PnC neuronal activity during PPI in vitro at inter-stimulus
intervals of 300 and 1000 ms (Bosch and Schmid, 2008). In January 2017, during the
BBRC seminar series, we were excited to host Dr. Susanne Schmid (from the University
of Western Ontario), a pioneer in the field. Her recent results using state-of-the art
chemogenetic and Optogenetic approaches further supported a minor contribution of
the PPTg cholinergic projections during PPI in vitro or in vivo (also see Valsamis et al.,
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2014 and MacLaren et al., 2014). Her results actually indirectly supported our
hypothesis that a PPTg-PnC glutamatergic connection might contribute to PPI.
The objective of Specific Aim 2 was to test the contribution of the PPTg-PnC
glutamatergic connection to PPI in vivo. An optogenetic approach was used to
selectively express light-sensitive channels in excitatory neurons from the PPTg that
hyperpolarize the cell in response to green or orange/yellow light, depending on the
virus that was used. The cells infected with archaeorhodopsin express proton pumps in
their membranes and open with green light leading to hyperpolarization of the
membrane (through an outward proton current). The cells infected with halorhodopsin
express chloride pumps in their membranes, also leading to hyperpolarization (through
an inward Cl current). We decided to use two different inhibitory opsins to confirm the
-

effects of inhibition due to photo-inhibition. We were also able to visualize the channelexpressing neurons due to the presence of the reporter gene eYFP contained in the viral
constructs and expressed in the excitatory neurons infected. At the end of the
behavioral testing, I extracted the brains of these mice and I performed
immunohistochemistry to reveal the chemical identity of the targeted PPTg neurons
and visualize the neuronal fibers and terminals within PnC slices. The data generated
from these experiments furthered our understanding of the modulation of PPI and
identified a potential new target for the development of treatments for patients
suffering from SG impairments.
II.2.2. Materials and Methods
Animals: Adult C57CBL/6 male mice aged between 1-2-month-old mice (Jackson
Laboratories) housed in the University of Texas at El Paso (UTEP) vivarium with
controlled temperatures and a 12-hour light / dark cycle have been used for these
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experiments. All protocols were conducted in compliance of the UTEP Institutional
Animal Care and Use Committee (IACUC).
Surgery / Viral injections: All injections were done with a pressure micro-injector
(Quintessential Stereotaxic injector, Stoelting Co., IL) 4-6 week-old-mice were injected
unilaterally. The following viral particles were injected intracranially and contained:
archaeorhodopsin, halorhodopsin, or only mCherry (i.e., AAV-DJ-CaMKIIa-mCherry, a
"control" viral construct devoid of opsin gene). A recent review by Mena-Segovia &
Bolam (2017) states that the glutamatergic neurons in the PPTg are more densely
concentrated in its caudal portion, hence we targeted that area for injection. Two
injections of 0.15 µL each (0.3 µL total) were administered using pulled glass
micropipettes in the following coordinates relevant to Bregma targeting the PPTg: #1
AP: -4.84 mm, ML: +1.3 mm, DV: -3.75 mm, and #2 AP: -4.84 mm, ML: +1.3 mm, DV: 3.5 mm. The mice were anesthetized with 1.5% isoflurane via inhalation through a nose
cone attached to the stereotaxic platform head holder for the entire duration of the
surgery.
Optic Fiber Implants: Three weeks post-injection, the mice were anesthetized
with 1.5% isoflurane via inhalation through a nose cone attached to the stereotaxic
platform head holder for the implantation duration of the optic fiber/ cannula (Thor
Labs, Newton, NJ). The optic fiber was held with an adapter to the stereotaxic platform
arm and the tip of the optic fiber measures a length of 5.0 mm and was lowered into the
following PnC coordinates: AP (Bregma) -5.34 mm, ML +0.7 mm, DV - 5.0. The
coordinates were chosen guided by the light dispersal equation given in Yizhar et al.,
2011. Once the optic fiber was positioned inside the brain, a mixture of C&B Metabond
(Parkell, Edgewood, NY) was spread across the skull and air-dried until it hardened.
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The adapter was then raised, and the optic fiber was left on the mice’s head for one
week (for recovery) until the behavioral tests were performed. The mice were allotted a
total time of four weeks post-injection for the virus to proliferate before the in vivo
behavioral studies.
In vivo Optogenetics Behavioral studies: The mice were quickly anesthetized
with isoflurane in an anesthesia chamber and the doric fiber was coupled to the tip of
the cannula. The light sources were either a PlexBright LD-1 single channel LED Driver
(1200 mA max) with a PlexBright green LED green emitting module (525 nm) (Plexon,
Dallas, TX) for the animals injected with archaeorhodopsin or an orange/yellow laser
source (P/N: MGL-F-593.1 ± 1 nm-100mW; Opto Engine LLC, Midvale, UT) for the mice
injected with halorhodopsin. Once the mouse fully recovered, it was let to walk freely in
its cage for 10 min and placed inside the startle testing chamber (Harvard Apparatus,
Holliston, MA) for another 5-10 min for acclimation before the experiments. The load
cell coupler module (Harvard Apparatus, Holliston, MA) detects the movement of the
mouse when it startles, which is connected to the main computer (HP Pro Desk 600,
Intel i5-6500@ 3.20 GHz, 4GB RAM; Hewlett Packard, Palo Alto, CA) and fed into the
Packwin v2.0 software (Panlab) (Harvard Apparatus, Holliston, MA), who correlates
the sound stimulus to the startle response and presents the data in an excel file, as well
as live traces. The following four different protocols were used for the behavioral
experiments: #1: Acoustic startle response with sound only, #2 Acoustic startle response
with “light on” (during the startling sound), #3 PPI only, and #4 PPI with “light on”
during the task. The intensities of the startling stimuli were delivered randomly at
different times to prevent habituation. We chose to use 75 db for the prepulse intensity
since it is the highest intensity at which none of the mice startled. The non-startling
prepulses and startling pulses of the PPI protocol were delivered randomly at different
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Inter-stimulus intervals (ISIs) to prevent adaptation of the animal. The experimental
procedure is summarized in Figure 2.2. The animals were taken out of the chamber for
10 min after each protocol and placed in their cages for a 10-minutes resting period
before starting the next protocol. This prevented a decreased response due to
adaptation of the animal to the startling chamber. Once the behavioral testing
completed, the mice were perfused as described previously in the Specific Aim 1
Surgery/neuronal tracer injections method section. Briefly, I extracted and fixed the brains
in 4% PFA and I sliced them in 30 µm sections encompassing from the caudal PnC to
the rostral PPTg.
Histological analyses: The brain slices collected containing the PPTg were
treated with an antibody against ChAT (1:100, which labels cholinergic neurons) to
delineate the cytoarchitectonic borders of the PPTg. The slices containing the PnC were
treated with an antibody against VGluT2 (1:300) in an attempt to label and visualize
excitatory synapses between the PPTg fibers/terminals and the PnC neurons, as
described previously in 4.1.3b. Briefly, the slices were incubated in NDS and a
combination of primary and secondary antibody solutions. In addition, the tissue was
Nissl-stained to further delineate cell bodies and anatomical borders.
Microscopy: The slides were examined under the Keyence BZ-X710 All-in-one
Fluorescence Microscope (Keyence, Inc. Elmwood Park, NJ) with filter sets of DAPI,
Alexa 488, Texas Red/Cy3, and FG to visualize fluorescence from the eYFP expressed in
the neurons and from the secondary antibodies used. The slices were further examined
under the Zeiss Observer.Z1 equipped with needed filter sets for Alexa 488, Cy5 to
visualize terminals in more detail.
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Figure 2.2. Schematic representation of the PPI protocol in vivo. Left, PPI protocol under control
conditions (ie, NO light). Right, PPI protocol with the photoinhibition of the PPTg-PnC excitatory
synapses with green or yellow-orange light (ie., light ON) at the level of the PnC. The light was turned on
1 ms before the prepulse and stayed on for 2 seconds. All the shown ISIs were performed 7 times in a
randomized order.
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Chapter III: Results
Understanding the PPTg-PnC connection and its functional role in SG requires
both visualizing the neuronal projections and assessing SG behaviorally. To visualize
the PPTg neurons connected to the PnC, I used both retrograde and anterograde tracing
methods. Then, to investigate the connection’s behavioral contribution to SG, I assessed
PPI behaviorally in vivo while photo-inhibiting the connection. The results from the
mentioned experiments are described below.
III.1. PPTg-PnC glutamatergic connection
To visualize and characterize the PPTg projections to the PnC, I used a total of 28
mice that I injected with the retrograde tracer FG and with the retrograde virus AAVrgCAG-tdTomato (N=4). I used another subset of mice that I injected with either
CTB(N=2), AAVDJ-CaMKIIa-eArch3.0-eYFP(N=6), AAVDJ-CaMKIIa-eNpHR3.0eYFP(N=6) or AAVDJ-CaMKIIa-mCherry(N=4) viral particles. Moreover, to confirm
the identity of the neurons that expressed the retrograde or anterograde tracers or
viruses, antibody staining against ChAT, GAD67 and VGluT2 were performed at either
the injection site or projection sites. An injection summary for both retrograde and
anterograde labeling experiments is in Appendix 1.
III.1.1. PPTg projections to the PnC | Retrograde labeling
Both FG and the retrograde viral particles were injected in a location to the right
side of the midline in the PnC for all mice as seen in Figure 3.1 A and B, which is a
representative example of the retrograde tracing experiments. The injection sites were
evaluated using the Paxinos and Franklin brain atlas (Paxinos & Franklin, 2014).
22

Adjacent sections were further treated with Nissl staining which allowed me to
delineate the brain region boundaries. In addition, the sections containing the PPTg
were treated with ChAT and GAD67 antibody staining helping me to visualize the
cholinergic and GABAergic neurons confined within the PPTg. In order to evaluate if
an injection targeted the PnC, I analyzed the injection site and its size from different
sections. When the injection was contained within the PnC boundaries dorso-ventrally
and rostro-caudally, I could confidently determine that the back-filled cells observed
within the PPTg projected to the PnC.
My results show that in sections that contained the PPTg, retrogradely labeled
neurons were observed within the PPTg as seen in Figure 3.1 C-G, which is a
representative example of the retrograde back-filled cells in the PPTg. Interestingly, two
observations were made. The first is that cell bodies were back-filled on both the
ipsilateral and contralateral sides of the injection side as seen in Figure 3.2. Also, some
cell bodies from both sides co-localize the expression of td-tomato and the ChAT,
showing that some of those back-filled cells are cholinergic, and they cross the midline
to the contralateral side. Also, some cell bodies expressing tdTomato do not co-localize
with cells stained with ChAT nor GAD67, suggesting a glutamatergic identity of the
back-filled cell bodies.
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Figure 3.1. Retrograde tracing.
(A) Wide-field image of a PnC containing slice of a WT animal (ID 919) injected with the AAVrg-CAG-tdTomato retrograde
virus in the PnC. The fibers expressing the reporter gene tdTomato are seen with a Cy3 filter. The injection site is inside the
white rectangle in the dorsal part of the PnC. (B) A close-up image of the injection site in the dorsal part of the PnC slice
shows a retention within the PnC boundaries. (C) A wide-field image of a PPTg containing slice of the same animal injected
in the PnC stained immunohistochemically for ChAT and GAD67 and showing tdTomato expressing fibers and cell bodies.
The PPTg of the injection side is enclosed with a white rectangle. (D) A close-up image of the PPTg of the injection side
revealing the boundaries of the PPTg by the abundance of cholinergic neurons revealed by the ChAT stain and showing
back-filled cell bodies expressing tdTomato within the PPTg. (E, F, G) The same close-up image as D but showing the image
in the Cy3, GFP, and Cy5 filter, respectively, to show individual labeling.
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Figure 3.2. Contralateral retrograde filling.

(A) Wide-field image of a PPTg containing slice of a WT
animal (ID 923) injected with the AAVrg-CAG-tdTomato
retrograde virus in the PnC. The fibers expressing the
reporter gene tdTomato are seen with a Cy3 filter and the
PPTg on both sides delineated by ChAT immunostaining.
(B) A close-up image of the injection side on the left-side
of the PPTg showing cell bodies expressing tdTomato and
co-staining with ChAT within the PPTg. (C) A close-up
image of the PPTg of the contralateral side of the injection
containing slice of the same animal injected in the PnC
showing tdTomato expressing fibers and cell bodies and
co-staining within the PPTg.
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III.1.2. PPTg projections to the PnC | Anterograde labeling
As previously mentioned, I used a subset of animals for the anterograde tracing
experiments, using the animals that had performed the behavioral experiments. CTB
and all the viruses used for these experiments were injected in the caudal PPTg of the
right hemisphere of the brains in WT mice. The caudal PPTg was chosen due to a recent
review by Mena-Segovia and Bolam, 2017, mentioning the concentration of
glutamatergic neurons in the caudal PPTg. The injection and projection sites were
evaluated using the Paxinos and Franklin brain atlas (Paxinos & Franklin, 2014). The
brain sections containing the PPTg and the PnC were stained in a similar fashion as
those described in the retrograde labeling section. The slices containing the injection site
in the PPTg were stained for ChAT and some with Nissl. The slices containing the PnC
were analyzed for the expression of fluorescent fibers within the PnC, which suggest
that neurons injected within the PPTg send fibers to the PnC. After enhancing the
fluorescence of CTB in a series of slices, it was evident that an accurate injection was
performed in the PPTg, but it was quite difficult to find fibers in the PnC, as seen in
Figure 3.3. Due to the faint fluorescence of CTB, we decided to use the viral particles as
anterograde tracers. Fibers expressing eYFP were found in the PnC 4-6 weeks postinjection as seen in Figure 3.4.
From the viral construct used, eYFP expression was driven under the control of
the CaMKIIa promoter, suggesting that the eYFP-expressing neurons are excitatory. My
results show that some cells within the PPTg seemed to express both eYFP and ChAT,
suggesting some PPTg cells can co-release ACh and glutamate as neurotransmitters. It
is also possible that cholinergic and glutamatergic cells were very closely intermingled.
Other PPTg cells were only expressed eYFP, strongly suggesting a glutamatergic
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identity as seen in Figure3.4 B. There were several areas within PnC sections in which
the PPTg eYFP-expressing fibers could be observed. The expression of eYFP was more
predominantly seen at the ventro-medial part of the PnC, with some fluorescence on the
contralateral side as seen in Figure 3.4 D. I also performed VGluT2 staining in order to
identify the chemical nature of the fibers expressing eYFP. Since there is a major
abundance of glutamatergic synapses within the PnC, with many areas projecting to it
and its nature of having the giant glutamatergic neurons, the VGlutT2 stain showed
major fluorescence all along the PnC and it was impossible to identify if the fibers were
truly co-localizing with the stain or adjacent tissue was causing background
fluorescence (not shown).

Figure 3.3. CTB Injection. Coronal sections showing the injection site in the PPTg (A), and the CTBfluorescent PPTg fibers within the PnC (B). (A) Inset, High-magnification of the injection site at the
PPTg with labeled cell bodies. (B) Inset, High-magnification of the projection site at the PnC with
labeled axonal terminals.

27

Figure 3.4. Anterograde Labeling and optic fiber implantation.

(A) Wide-field image of a PPTg containing coronal slice of a WT animal (ID 724) injected with AAVDJ-CamKIIαeNpHR3.0- eYFP (halorhodopsin) in the PPTg. The cell bodies and fibers expressing eYFP were enhanced
immunohistochemically and visualized with a GFP filter. The tissue was treated immunohistochemically for ChAT
(Cy3) to reveal PPTg boundaries and identify neuronal identities. (B) A close-up image of the injection site in the PPTg
showing cell bodies expressing eYFP and some co-staining with ChAT within the PPTg. (C) A wide-field image of a
PnC-containing slice showing fibers expressing eYFP projecting from the PPTg. A tract from the optic fiber
implantation can be seen ventro-laterally to the 4 ventricle with the tip terminating within the boundaries of the PnC.
(D) A close-up image of some PPTg fibers expressing eYFP within the ventro-lateral portion of the PnC.
th
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III.2. Behavioral assessment of the PPTg-PnC synapse
To determine the contribution of our characterized glutamatergic PPTg-PnC
connection to SG in vivo, I photo-inhibited the connection during the PPI task. A total of
16 mice were injected with either AAVDJ-CaMKIIa-eArch3.0-eYFP (archaeorhodopsin,
N=9, n=6), AAVDJ-CaMKIIa-eNpHR3.0-eYFP (halorhodopsin, N=9, n=6), and AAVDJCaMKIIa-mCherry viruses (no opsin, N=5, n=4) and used for the behavioral
experiments. Some mice could not be used for the behavioral experiments and were
only perfused and the tissue used for visualization. The main purpose of
archaeorhodopsin and halorhodopsin is to inhibit those PPTg fibers expressing eYFP in
the PnC while assessing ASR and PPI in vivo. I also used a viral construct devoid of
opsin gene, as a "control" injection. As mentioned before, the fluorescence from these
experiments was also used as the anterograde labeling technique for Specific Aim 1. To
confirm the identity of the neurons targeted by the viral injections, antibody stains with
ChAT and VGluT2 were performed at either the injection site or projection sites. In
addition, I visualized and confirmed proper optic fiber implantation with the brain
slices using immunohistochemistry. A summary of the injections performed for these
experiments is included in Appendix 1.
III.2.1. Acoustic Startle Response
In order to assess PPI, the acoustic startle response (ASR) has to be assessed first
to evaluate the animal’s basal startle levels and find the sound level needed to elicit a
"non-startling" response (or "prepulse"). The ASR was measured using the first two
protocols described in the II.1.2. Materials and Methods section of Chapter II. The first
protocol was used to measure basal startle levels, and the second protocol was used to
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confirm that photo-inhibition of the PPTg fibers in the PnC does not affect the acoustic
startle response, since the PPTg is not involved in the ASR pathway. The experiments
were performed using the mice I injected with either one of the three viral particles
mentioned above, 4 weeks post injection and one week following cannula implantation.
Behavioral experiments began with a period of five minutes of exploration, then
the ASR was assessed by presenting the mice with pulses of different intensities in a
randomized order with the light off during the whole experiment. Following the
“Light-off” protocol, the second protocol was performed in a similar manner, but now
with the “Light-on” condition where the light, either green (for archaeorhodopsin
injected mice) or yellow/orange (for halorhodopsin injected mice), turned on, one
second before the pulse was presented and turned off one second after. My results show
an Increased startle reaction as a function of sound Intensity. Interestingly and as
expected, I was happy to confirm that the sound intensity-dependent increase in the
ASR did not differ between the “light-on” and “light-off” protocols across all the
conditions tested (i.e. by the two inhibitory opsins and control virus), as seen in Figure
3.5.
III.2.2. PPTg-PnC Synapse silencing during PPI
The ASR protocol allowed us to select the sound intensity low enough to be used
as a prepulse (i.e., a detectable sound that did not startle the animal) as well as a sound
intensity loud enough to be used as a startling pulse (i.e., a sound level at which all
animals startle). The values chosen were 75db for the prepulse and 120db for the
startling pulse. Protocols #3 and #4 were designed to measure changes in PPI. Protocol
#3 was the “PPI light-off” and Protocol #4 was the “PPI light-on” condition where the
light turned on one second before the prepulse and turned off one second after the
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startling pulse for any given inter-stimulus interval (ISI). The prepulse and the
subsequent startling pulse were presented every 29 seconds at different ISIs in a
randomized fashion for both protocols. The basal startle level was also evaluated
throughout the entire extent of the experiment, as described by Diamantopoulou et al.,
2017. I therefore used this basal startle level to calculate the PPI values. Each ISI was
presented seven times and averaged for analysis purposes.
Both Protocols, #3 and #4 were compared to each other to analyze any change in
PPI induced by silencing the PPTg-PnC connection, as shown in Figure 3.6. The control
mice showed no significant change in the basal startle responses between the protocols.
Since these mice were only Injected with a viral vector devoid of Opsin gene, these mice
still exhibited PPI, but the "Light On" condition did not produce any change in PPI.
These results were expected since the cells infected with this "control" viral construct do
not express any Opsin protein (i.e., no inhibitory channel in their membrane) but only
express mCherry. These data suggest that if any change in PPI is observed by the
shining light on the PPTg fibers projecting onto the PnC, this change will likely be due
to the photoinhibition of the PPTg fibers and not due to an undesired effect of the
injection or optic fiber implants themselves.
The mice injected with archaeorhodopsin showed no significant change in the
basal startle responses when the "Light Off" and "Light On" protocols were compared.
Regarding PPI, these mice exhibited normal PPI under "Light Off" conditions.
Interestingly, when the PPTg-PnC excitatory connection was inhibited by the green
light (i.e., "Light On" condition), a lowered startle response was elicited, which resulted
in an increased inhibition of the startle response, in other words, an increased PPI.
These exciting results were contrary to what we were expecting (as discussed below)
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and the difference in PPI was statistically significant at the 500 ms ISI (p = 0.027) as seen
in Figure 3.6, middle.
To confirm the Archaerhodopsin effects on PPI, we also used another Opsin, i.e.,
Halorhodopsin, for comparison purposes. The mice injected with halorhodopsin did
show a decrease in the basal startle responses when the PPTg-PnC excitatory connection
was inhibited by the orange light compared to when the light was off. An explanation
for these results is provided in the IV.2.2 ASR and PPI section of Chapter IV. Moreover,
the photoinhibition of the PPTg-PnC excitatory connection with this Opsin also affected
PPI efficiently, and the mice also showed a lowered startle response when the light was
on, as seen in Figure 3.6, bottom. The results of these experiments show a trend on PPI
similar to those obtained with archaeorhodopsin. Altogether, these results strongly
suggest that the inhibition of the PPTg-PnC glutamatergic connection by different
opsins increases the inhibition of the startle response or PPI.
After the completion of the behavioral experiments, the mice were transcardially
perfused, and the brains sliced and treated with different antibodies to confirm
neuronal identities and a correct optic fiber implantation targeting the PPTg fibers in
the PnC with light. All of the mice included in the results section had a correct optic
fiber implantation as seen in Figure 3.4 C, showing a PnC section with labeled PPTg
fibers, closely positioned to the optic fiber tract. As also discussed in the anterograde
tracing section of the results, the VGluT2 stain could not be used to identify the
chemical nature of the opsin expressing fibers since it could not be distinguished from
the high background expression. In addition, from the slices containing PPTg, I have
evidence confirming that the injection was confined within the borders of the PPTg as
seen in Figure 3.4 A, which is a representative image of all the injections targeting the
PPTg used for the behavioral tests of this project.
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Figure 3.5. Acoustic Startle Response.

Shows the different intensities at which the
experiments were performed and the startle
responses of the animals. (Top) The responses of
the Animals injected with AAVDJ-CaMKIIamCherry (N=5, n=4) (Control animals). (Middle)
The responses of the animals injected with AAVDJCaMKIIa-eArch3.0-eYFP (N=9, n=6) .(Bottom) The
responses of the Animals injected with AAVDJCaMKIIa-eNpHR3.0-eYFP (N=9, n=6).
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Figure 3.6. Prepulse Inhibition.

Shows the assessment of PPI of the animals
manipulated with different opsins and silencing
the PPTg-PnC glutamatergic synapses. (Top)
Shows the PPI of the animals injected AAVDJCaMKIIa-mCherry (N=5, n=4) (Control
animals) which show a significant difference in
the 10ms ISI. (Middle) The responses of the
Animals injected with AAVDJ-CaMKIIaeNpHR3.0-eYFP (N=9, n=6) which shows a
significant difference in the 500ms ISI. (Bottom)
The responses of the animals injected with
AAVDJ-CaMKIIa-eArch3.0-eYFP (N=9, n=6)
showing no significant difference between the
conditions. All the results show a trend of
potentiated PPI when the light is on vs. when
the light is off conditions.
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Chapter IV: Discussion
The goal of this project was to determine a PPTg-PnC glutamatergic connection
that contributes to PPI. This was done first by characterizing and confirming a direct
anatomical connection between the PPTg and the central PnC and second, by assessing
its functional contribution to SG. The approaches taken to study this neuronal
connection can be seen in Chapter II. Briefly, tract tracing coupled to immunostaining
experiments were performed in parallel to in-vivo optogenetics experiments to address
these goals. For the tracing experiments, FG and the AAVrg-CAG-tdTomato virus were
used for retrograde labeling while CTB, the AAVDJ-CaMKIIa-eArch3.0-eYFP
(archaeorhodopsin), AAVDJ-CaMKIIa-eNpHR3.0-eYFP (halorhodopsin), and AAVDJCaMKIIa-mCherry ("control" vector) viruses were used for anterograde labeling. Early
studies had focused on and described a cholinergic connection between the PPTg and
the PnC (Koch et al., 1993; Swerdlow et al., 2001) and was initially thought to be the sole
contributor to SG. However, recent studies have suggested that the PPTg-PnC
cholinergic connection plays a modest role in SG (MacLaren et al., 2014), that the
cholinergic involvement in PPI could be originating from a different part of the brain
(Schmid et al., 2008) and that perhaps a glutamatergic connection could have a bigger
impact on SG assessed using PPI (Bergeron et al., 2015). Moreover, most studies were
performed in rats, without focusing on glutamate neurotransmission. Our research
efforts aimed at focusing specifically on a PPTg-PnC glutamatergic connection in mice
in efforts to understand its involvement in SG by being at the core of the PPI circuitry.
In addition, many SG deficits can be induced by blocking or altering glutamate
neurotransmission (Valsamis et al., 2014).
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Our tract tracing results show that a PPTg-PnC glutamatergic connection does
exist, and that it contributes to SG in vivo, in mice. Injections of the retrograde
tracer/virus in the PnC show back-filled cells in the PPTg, and injections of anterograde
tracer/viruses in the PPTg show terminals in the PnC. A glutamatergic identity of this
connection was confirmed with immunohistochemistry experiments. Moreover, photoinhibition of the PPTg-PnC glutamatergic synapse while assessing SG in vivo showed an
increase in PPI, suggesting a functional contribution of this synapse in SG.
These experiments provide information about a novel synapse, supporting
previous evidence showing that the PPTg is involved in SG but through a glutamatergic
connection, instead of a cholinergic connection. It would be interesting to test the
properties of the PPTg-PnC glutamatergic synapses and their involvement in SG using
translational animal models of disease, specifically those exhibiting SG deficits. Then,
subsequent genetic studies would provide a more molecular insight about the causes of
SG deficits in such disorders and thus identify potential targets for therapeutic
interventions and treatments.
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IV.1. PPTg-PnC glutamatergic connection characterization
IV.1.1. Injecting FG and AAVrg in the PnC
FG and AAVrg were used to trace the PPTg-PnC projections retrogradely in our
experiments. Initially, only FG was going to be used due to previous studies using it to
characterize the PPTg-PnC connection. Although FG is a great tracer and yields great
fluorescence within a short time post-injection, as explained by Schmued and Fallon,
1986, FG contains several caveats. FG is taken up by axonal terminals and up to the cell
body via kinesins that are found all along the axons. One of the problems with this is
that FG is easily taken up by damaged fibers of passage, which are commonly caused
due to the pipette entry damage on the tissue. Moreover, the tracer is a heavy and
viscous fluid when diluted, which tends to clog pipette tips that generally leads to the
need of using wider tips, thus resulting in larger injection sites. Such large injections are
hard to retain within the boundaries of the PnC, creating the possibility of back-filling
other cells with axons ending in close proximity to the PnC, but not within it.
The PPTg lies rostral to the PnC in the brainstem. Fortunately, it has been
described that the PPTg sends most of its projections rostrally, and only a few caudally,
going either to the PnC, or straight to the spinal cord ventrally to the PnC. Due to the
nature of the injections, when the tracer spills out of the boundaries, they are either
lateral or dorsal to the PnC, where PPTg has not been described to have projections
passing by other than those projecting into the PnC. A spilled injection in the PnC could
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lead to back-filled cell bodies in other areas, but here we focused on back-filled cells in
the PPTg, as our main interest.

Figure 4.1. FG- expressing neurons in the PPTg. Coronal sections showing the injection site (A, PnC)
and the back-filled neurons (B, PPTg) with FG (light blue) tracer. (A) inset, High-magnification of
injection site at PnC. (B) inset, High-magnification image of Back-filled cell bodies in the PPTg.

I achieved a few successful FG injections confined within the PnC borders as
seen in Figure 4.1. However, due to the difficulty of the FG injections, we decided to use
the retrograde virus AAVrg-CAG-tdTomato. The first type of this adeno-associated
retrovirus (AAV2-retro) that infects in a retrograde fashion was first described by Tervo
et al., 2016. The group reports that in a set of experiments labeling cortical neurons, with
the injection site in the basal pontine nuclei, showed that the density of the neurons
labeled by the retrograde virus was comparable to that achieved with FG, which is a
synthetic tracer that labels robustly. We opted to use the retro virus created by the team
of Dr. Edward Boyden (MIT) that contains the CAG promoter, which is non-selective in
the mammalian genome and yields high levels of expression of the tdTomato
fluorescent protein in neurons. Further studies are necessary to determine of the
function of these new viruses in terms of in vivo Optogenetic manipulations (Tervo et
al., 2016; Kobayashi et al., 2018; Sun & Schaffer, 2018).
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The PnC is an area in the ventral portion of the brainstem that expands in a quite
large area in the rostro-caudal plane. When trying to find the PnC in some sections, it
was difficult to distinguish it from the oral pontine reticular nucleus (PnO), since they
are very similar and occur adjacently. The PnO lies rostral to the PnC, which is closer to
the PPTg. However, it was not very difficult to find the PnC after using the Nissl
stained tissue to locate the injection site, which gives us features that we can compare in
the Paxinos & Franklin mouse Brain atlas, such as the 7th nerve.
The brainstem is known for regulating various vital physiological roles, such as
breathing. In addition, many motor centers are contained within it and damage to these
areas can cause great damage to the animals, even death. One of the greatest difficulties
with the injections in the PnC was the survival of the animals. Due to the limited control
of the FG injection volumes, a massive amount of the heavy tracer would be injected
and expand the tissue, causing damage and pressure on vital areas. Due to this, many
animals would wake up with evident muscular contractions or seizures and eventually
stop breathing and die within a short time after the injection. Some animals did show
these reactions to the injections but recovered successfully.
This type of tracing experiments using FG have been performed since the midlate 1900s and are still used. An alternative procedure to the FG pressure injections
could be implemented by using iontophoretic injections instead (Schmued & Heimer,
1990). Iontophoretic injections lead to small injection sites by ejecting the tracer of the
pipette via an electrical current, thus having more control over the volume injected.
Alternatively, we chose to use the state-of-the-art AAVrg which has been recently
developed and available, allowing for high expression and fluorescence of tdTomato in
axons and cell bodies. As mentioned, our interest in the PnC is due to its core
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involvement in the PPI neural circuitry and is still highly uncharacterized. The
injections of the retrograde tracers are vital in order to have a larger understanding of
the core circuitry of PPI while coupling them with anterograde tracing experiments and
confirming the neuroanatomy of this connection.
IV.1.2. Observation of back-filled neurons in the PPTg
As seen in the results section, the injections of the retrograde virus were
contained within the boundaries of the PnC and showed high expression of the
tdTomato protein along the fibers. Nissl and ChAT stainings were performed on this
tissue to identify the boundaries of the PPTg. The ChAT staining served two purposes:
1- to further characterize the identity of the cells expressing (or devoid of) tdTomato,
and 2- to delineate the PPTg is by identifying it by its high density of cholinergic
neurons.
In the PPTg containing slices, tdTomato expressing ascending fibers are seen
along the slice and interestingly in cell bodies within the PPTg on the ipsilateral and
contralateral side of the injection. The ChAT stain identifies the presence of cholinergic
neurons, and it co-stains a few td-tomato expressing cell bodies on both sides as seen in
Figure 3.2. It was expected that the cell bodies co-stained with the ChAT, since the
neurons expressing tdTomato are under the control of the CAG promoter, which is nonspecific to the mammalian genome, and it is known that cholinergic neurons project to
the PnC and cross the midline (Rye et al., 1987; Koch et al., 1993). In addition, we also
performed a GAD67 stain, which did not show co-localization with the back-filled cells
as seen in Figure 3.1 D, G. The fact that they did not co-localize in our experiments does
not rule out the possibility that a PPTg-PnC GABAergic projection could be present
since the cell bodies could be present at a different location within the PPTg. Also, the
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injection of the retrograde virus does not cover the whole PnC meaning that these
terminals could be present at a part of the PnC that was not injected with the virus.
Moreover, most importantly, there were also cell bodies within the PPTg expressing
tdTomato that did not co-localize with ChAT nor GAD67, strongly supporting our
hypothesis of the presence of a PPTg-PnC glutamatergic connection.
IV.1.3. Injecting CTB and AAVDJ-CaMKIIa in the PPTg
The first anterograde tracer injections for this project were done with CTB. CTB is
normally used as a retrograde tracer, but it can also serve as an anterograde tracer
(Angelucci et al., 1996). The tracer can be seen with an Alexa488 filter (green), but due to
low expression we decided to enhance the fluorescence with antibodies and make the
anterograde terminals more evident. Although CTB is a good tracer, we did not see
much expression, even with the enhanced fluorescence as seen in Figure 3.3. As an
alternative experiment, we decided to take advantage of the injections performed for
the behavioral section of the project (Specific Aim 2). The injections targeted the PPTg,
where the cell bodies are infected with the viral construct containing the opsin gene
and/or the reporter gene (mCherry or eYFP) and the translated proteins are expressed
in the membrane of the axons and terminals in an anterograde fashion.
The PPTg is involved in many functions and is very important in arousal. It
encompasses from -4.16 mm through -4.96 mm from bregma in mice (Paxinos &
Franklin, 2014). The PPTg is ventrolateral and in close proximity to the cerebral
periaqueductal gray (PAG) and can be sometimes confused with the laterodorsal
tegmental nucleus (LDTg) since they are also in very close proximity and almost
adjacent in more caudal parts of the PPTg. Due to the small area of the PPTg, it is
sometimes difficult to retain the injection within its boundaries, and it sometimes spills
to the LDTg. It has been demonstrated that the LDTg also projects to the PnC but is
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involved in locomotor activity, rather than startle (Takakusaki et al., 2016). Therefore,
injections that spilled into the LDTg were not considered for the results section since
inhibition of these fibers could alter our results during the PPI tests. In addition to the
literature showing that there are no other areas within the plane of the PPTg, other than
the LDTg, that project to the PnC, we analyzed injections that missed the PPTg and
targeted the lateral parts of it, close to the medial and inferior lemniscus and showed no
fibers expressing eYFP in the PnC. With this observation, we decided to consider the
injections that hit the PPTg and spilled over laterally and dorsally since they would not
affect the results for Specific Aim 1 or Specific Aim 2.
The PPTg is known to be part of the biggest cholinergic center in the brain and it
is strongly characterized by containing a high density of cholinergic neurons. In order
to delineate its borders, a ChAT antibody is commonly used to stain the cholinergic
neurons (Rye et al., 1987). The viruses injected in the PPTg contained the CaMKIIa
promoter which targets the neurons expressing the Ca2+/calmodulin-dependent
protein kinase II, seen specifically at excitatory neurons. In addition to the cholinergic
neurons, the PPTg also contains GABAergic and glutamatergic neurons (Wang &
Morales, 2009), and it is known that the cholinergic neurons relevant to SG are
inhibitory in the PPTg-PnC synapses (Swerdlow et al., 2001; Fendt et al., 2001; Schmid
et al., 2006) but not all the cholinergic neurons project to the PnC. This means that the
other cholinergic neurons in the PPTg are not necessarily inhibitory.
As expected, after immunostaining the tissue for ChAT and enhancing the
fluorescence of the cells infected in the PPTg slices, we confirmed that there are
excitatory cell bodies that are stained with ChAT, and there are also cell bodies that
only express eYFP within the PPTg, which suggest being glutamatergic as seen in
Figure 3.4 A, B. Ideally, we should use an antibody to label glutamatergic cell bodies
and ultimately test their synaptic contribution in vitro, using electrophysiology in brain
slices.
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IV.1.4. Observation of PPTg fluorescent terminals in the PnC.
Four weeks post-injection, resting period during which the virus can proliferate,
my results show that there are fibers in the PnC that express eYFP and that emerge from
the PPTg. Since the fibers are only expressing eYFP, we were not able to determine their
chemical identity solely by labeling. Therefore, we decided to use antibodies to target
VGluT2 since it is used to target the vesicular glutamate transporter 2 which is found
almost exclusively on axons and terminals. The PnC slices were treated to enhance the
eYFP fluorescence and to label glutamatergic axons and terminals, but the labeling too
dense, preventing the clear distinction between fibers within the PnC that originated
from the PPTg. The PnC is a large area receiving inputs from various sources, largely
glutamatergic (reviewed in Fendt et al., 2001). In fact, past and current projects from our
laboratory show that there are glutamatergic projections from the medial pre-frontal
cortex (mPFC) and the basolateral amygdala (BLA) in mice. In addition, the PnC
contains a great abundance of glutamatergic receptors and neurons that could have
synapses within the same area, being easily labeled by the antibody against VGluT2.
Since it was shown that the cholinergic neurons from the PPTg had an inhibitory
effect on the PnC giant neurons, we proposed that the excitatory fibers expressing eYFP
in the PnC that are involved in PPI must be glutamatergic. This was further confirmed
by the behavioral experiments with the light targeting all the eYFP expressing fibers in
the PnC, but only the glutamatergic ones had an effect on PPI, as seen in the results
section. There have been recent studies proposing that the PPTg cholinergic neurons are
not involved in PPI, which what has led us to perform this study, and supports our
motive to postulate that the excitatory neurons seen in the PnC emerging from the PPTg
are the ones involved in PPI.
Most of the fluorescence from the PPTg fibers on the PnC was seen on the
ipsilateral side of the injection, but there were also some fibers seen along the midline
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and on the contralateral side supporting what was seen in the retrograde injections
section. It would be interesting to study if there is a specific contribution from the
glutamatergic neurons in PPI by synapsing onto the different sides of the PnC.

IV.2. Behavioral tests and optogenetic inhibition
IV.2.1. ASR and PPI
The primary goal of this project was to identify if PPTg-PnC glutamatergic
synapses are involved in SG and were assessed using the PPI task. To do so, I made the
PPTg-PnC synapses express archaeorhodopsin (a proton pump) and I silenced them
with green light. I could have shined light on the whole PPTg and silenced all the
excitatory neurons within it to assess PPI, but this could probably yield different results
since the PPTg is involved in many other systems like sleep/wake cycles, arousal and
rate of locomotor output. Affecting the behavioral state of the animal (i.e. induce
drowsiness/tiredness) could affect the startle levels and yield other results. Since we
were interested in this specific connection, I implanted the optic fiber, so the tip could
be on the dorsal portion of the PnC and the light reach most of the PnC. A correct
implant placement was confirmed imaging fiber tract made by the canula and optic
fiber in PnC brain slices. My behavioral results also show that the PPTg glutamatergic
fibers on the PnC neurons indeed contribute to PPI. In these type of studies, a laser light
source is generally used to reach deeper into the tissue with higher power, but due to
the overwhelming cost of such equipment, we used a green LED light source which
yielded significant results.
For all of the animals tested, we recorded startle responses with the light turned
off and compared them to the responses when the light was turned on, using the same
animal (as internal control). In order to control for the physical and unspecific effects
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that the actual injections, optic fiber implants, or light could cause, I injected different
animals with the AAV-DJ-CaMKIIa-mCherry vector which do not affect neurons
activity. This design was performed in order to confirm the actual effects of inhibiting
the glutamatergic PPTg-PnC synapses in PPI. There were no significant changes seen in
the control subjects in neither the ASR tests, but there was a significant difference in the
10ms ISI for PPI. Since there are only a few samples to average for the control
experiments, this might have caused this significant difference. In order to confirm that
this effect is due to the low sample number, or the manipulations, more experiments
need to be performed to decrease the standard error. This is needed to show that the
unspecific manipulations of the injections or light penetration do not account for the
changes seen during the inhibition of the synapses with a different vector, since this
should not be a factor contributing to the results seen.
To confirm the results seen with one inhibitory opsin, we decided to use the
same approach but with a different opsin (ie., halorhodopsin instead of
archaeorhodopsin). The ASR results for the animals injected with both viruses showed
no difference between the dependence of the startle levels on the sound intensity, which
is expected since the PPTg is not involved in the ASR pathway. The PPI protocols
compare the startle of presenting a prepulse before the starling pulse (yielding to
prepulse inhibition) to a pure startle response elicited by the startling sound spread
throughout the protocol. Since the PPTg is not involved in the ASR pathway, the startle
response within the PPI protocol should not change significantly within the same
animal when the light is turned off, compared to when the light is on. In contrast to my
archaeorhodopsin results, in the animals injected with halorhodopsin, the light altered
the startle responses. Surprised by this unexpected and obviously wrong result, we
uncovered the cause of this error: the gain of the software (but not that of the load cell
coupler) was lowered, hence giving a lower startle response. The gain that is normally
manipulated is the one of the load cell coupler, but due to software issues the settings
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were reset to factory, and we did not account that the gain from the software had to be
re-adjusted back to the level in which the rest of the animals were tested on. This could
explain the lowered startle response in the halorhodopsin injected animals. Despite the
difference in startle levels, the trend of PPI seen in the halorhodopsin injected animals
was similar to the one seen in archaeorhodopsin injected animals. All the ISIs showed a
trend of lower PPI values when the light was on (I.e. when the PPTg-PnC excitatory
synapse was silenced), but the 500ms ISI was the one that showed the most robust PPI
change. In order to confirm these results and be able to show differences with
confidence, the experiments using the inhibitory opsins have to be performed on more
mice, and the ones with halorhodopsin with the gain adjusted to the original setting.
It was previously mentioned that the results obtained were not expected since
theoretically the silencing of this connection should lead to a decreased PPI, which is
normally seen in people suffering from disorders characterized by SG. Interestingly, the
silencing of the PPTg-PnC glutamatergic connection has yielded results similar to those
seen in a mouse model of autism (Stark et al., 2009). In this model, a decrease in PPI was
seen in the 100ms ISI and at different prepulse intensities. It is interesting to see that the
silencing of this PPTg-PnC glutamatergic connection expresses a response very similar
to the impaired SG of a model of disease. To further test this, this model of disease
could be analyzed to look at the PPTg glutamatergic neurons and identify if there is any
difference compared to a wild type and possibly identify a strong involvement in the
impairment of SG.
As stated initially, we were expecting that the PPTg glutamatergic neurons had
an effect on PPI, and since the PPTg contribution to PPI is inhibitory, we were expecting
for them to synapse onto the PnC glycinergic interneurons and inhibit the giant
glutamatergic neurons. If this would be the case, inhibiting the PPTg glutamatergic
neurons would lead to a decreased PPI, but this was not what was seen. Contrary to
what we were expecting, by inhibiting these neurons the PPI is potentiated, suggesting
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that other components could be contributing to this mechanism. These data are
suggesting that the PPTg-PnC glutamatergic synapses could possibly directly excite the
giant glutamatergic PnC neurons, and when these synapses are inhibited, a different
input would be unmasked leading to an enhanced inhibition (PPI). We have proposed a
PPTg-PnC circuit relevant to SG seen in Figure 4.2, where there is also a GABAergic
projection emerging from the PPTg to the PnC and when the glutamatergic neurons are
silenced, a contribution from such neurons is unmasked and they directly inhibit the
PnC giant glutamatergic neurons that mediate the startle. In order to test this, the next
procedures would be to try to evaluate the contribution of the PPTg GABAergic
neurons to PPI at the level of the PnC.
Since we have proposed a GABAergic component into the PPTg-PnC synapses, a
possible explanation to the altered results seen in the animals injected with
halorhodopsin could be due to the nature of the channel allowing the selective flow of
chloride ions. The translation of archaeorhodopsin leads to the expression of proton
pumps in the neuronal membranes, leading to inhibition of the cells by expelling
protons out of the cells and thus hyperpolarizing the membranes. On the other hand,
the translation of halorhodopsin leads to a chloride pump in the membranes of the cells,
leading to inhibition by taking chloride ions into the cells and hyperpolarizing the
membranes. The terminals of the glutamatergic neurons expressing halorhodopsin are
inhibited at the level of the PnC, where the synapses affecting PPI must occur. Based on
our proposed PPTg-PnC circuit, the glutamatergic and the GABAergic processes on the
PnC are in close proximity synapsing onto the giant glutamatergic neurons, the use of
halorhodopsin could affect the concentrations of chloride ions in the extracellular space
altering the natural function of the GABAergic neurons when the light is shined. We
only saw an abnormal startle response when the light was on in the halorhodopsin
injected animals, and not on the archaeorhodopsin animals and a chloride ion
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concentration manipulation could be an explanation, but as mentioned before, more
experiments need to be performed to confirm this effect, or to rule out this possibility.
Another possible explanation to these results could be a presence of group II
metabotropic glutamatergic receptors (mGluR2/3) in the PPTg-PnC connection relevant
to SG as seen in a similar connection relevant to SG (Valsamis et al., 2014). These
receptors happen in the pre-synaptic terminals and have an inhibitory effect by
preventing neurotransmission, and not activating the subsequent cells. Further studies
also have to be performed in order to confirm this proposed involvement.

Figure 4.2. Proposed PPTg-PnC circuit relevant to SG. The diagram shows a proposed PPTGPnC circuit. The (Left) panel represents the PPTg, containing cholinergic, glutamatergic, and
GABAergic neurons that are projecting onto the PnC. The (Right panel) shows the PnC
containing the PPTg afferents synapsing onto glycinergic interneurons, or the giant
glutamatergic neurons, who then project to the spinal cord. It is proposed that the (inhibitory)
cholinergic neurons don’t contribute to SG in this circuit, (excitatory) glutamatergic neurons
synapse onto (inhibitory) glycinergic neurons and giant glutamatergic neurons, and the
(inhibitory) GABAergic neurons project onto the giant glutamatergic neurons.
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IV.3. Future Studies
The main purpose of this project has been to identify a putative connection at the
core of PPI and test its involvement functionally. The results of this project have
demonstrated a circuit that has not been described before. The techniques that have
been used are tract-tracing experiments and in-vivo optogenetic silencing while the
animals perform the PPI tasks. What these results have revealed is that there is a
glutamatergic involvement in PPI at a specified ISI, but more experiments need to be
performed to see if they are involved in more than one ISI. Now that we have shown
this type of involvement, many more questions can be asked about this circuit and the
mechanism. Future studies for an in-depth understanding of this mechanism and newly
described circuit can be performed to look at the electrical and molecular characteristics
of the glutamatergic PPTg-PnC synapses.
The following studies to further support our initial hypothesis and results could
be done by obtaining in vitro extracellular recordings with an optogenetic approach. The
virus AAVDJ-CaMKIIα-ChR2-eYFP could be injected directly to the PPTg and
selectively make the glutamatergic neurons excitable with blue light. To test this
connection in vitro, we could mimic the PPI task in PnC slices with electrophysiological
techniques, as previously published (Bosh and Schmid, 2008). After the viral
proliferation period, the brain would then be extracted and 300 µm-thick brain slices
would be obtained at the level of the PnC, which would contain the terminals of the
PPTg glutamatergic neurons that would be photo-excitable with blue light. The protocol
to follow would be to shine blue light at the PnC level, where the PPTg terminals are
located and excite them, simulating the prepulse. Subsequently, we would electrically
stimulate the auditory fibers to simulate a startling stimulus while performing
electrophysiological recordings. Then, a cocktail of glutamatergic receptor blockers
would be added; CNQX for AMPA receptors and AP5 for NMDA receptors to confirm
the glutamatergic nature of the synaptic inputs. We would expect to see a diminished
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PPI response after the drug treatment and recover the response by a washout. In
addition, a similar approach of analyzing SG in vivo while recording could be
performed in order to look at electrical activity and pair it with behavior.
It would be interesting to look at different aspects of this connection like
what types PPTg neurons specifically target the PnC. As described in Leinweber et al.,
2017, a combination of viruses can be used to specifically locate projection neurons at
very specific synapses. The experiment would be to inject AAV2/1-Ef1a-TVA-T2ACVS11G into the PnC to express the rabies virus G protein and TVA receptors in the
local PnC neurons. Then, the retrograde monosynaptic rabies virus would be injected 2
days after the AAV injection to specifically infect and label the cell bodies in the PPTg
synapsing onto specific PnC neurons. The brains of these animals would be extracted
and to further visualize this connection they would be treated immunohistochemically
to be able and identify their chemical nature. The AAV fluorescence would reveal the
cell bodies in the PnC and the rabies virus would label the PPTg-PnC projections. In
addition, it would be interesting to test if all the PPTg glutamatergic neurons are
involved in the modulation of PPI, or if there is a subset of them involved in other
activities.
Many studies and reviews have shown the areas that project to the PPTg and
regulate PPI, but they have not shown what is their contribution to the PPTg in function
to PPI. To identify these areas, injections of the monosynaptic rabies virus could be
performed targeting the PPTg and seeing which other areas project to them. After these
have been identified, a series of optogenetic manipulations could be performed on these
different areas while the animal is doing the PPI behavioral tasks in vivo to see the
identified area’s contribution to the PPTg.
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IV.4. Conclusion
The inability to focus attention due to brain overload becomes devastating when
it is involved in your daily life. People suffering with many neurological disorders
suffer from such attention deficit as a result of a faulty SG mechanism, which reduces
their daily life quality. Many research efforts have been made throughout the years to
understand the nervous system, but due to the lack of understanding and the late
emergence of new techniques, there are still disorders that are yet to be understood. It is
imperative that many efforts are made to understand and be able to treat nervous
systems disorders due to its complete control over the body and develop possible
treatments.
For this project, I have identified a novel synapse at the core of the circuitry
modulating SG. This connection was identified by tract-tracing techniques and its
involvement was characterized by performing PPI in vivo, which allowed us to identify
the synapse’s function. More research has to be done to understand this connection’s
molecular involvement, in addition to the electrical activity leading to the decrease in
PPI seen when the connection was silenced. Moreover, it would be interesting to
determine if a problem in this connection leads to the impairments in SG, or if it is part
of it at least. The manipulation of this synapse has shown a similar effect of PPI as that
seen in a model of disease of autism. The analysis of this disease model could give more
insights to the determinants of the impairment of SG in neurological disorders.
Therefore, many more research efforts must be made in order to be able to develop
possible treatments and therapeutic interventions of this life-impairing deficit.
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Appendix 1: Injections Summary
AIM 1
INJECTIONS
ID
5296
5297
5070
5071
5072
5073
5074
5294
5295
5293
5031
5032
5023
5025
5024
7668
7667
7669
7272
7273
31
33
32
34
500
499
235
236
7677
7269
919
923

TRACER
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
FG
CTB
CTB
AAVrg
AAVrg

AIM 2 INJECTIONS
INJECTION
AREA
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PnC
PPTg
PPTg
PnC
PnC

ID
963
1569
1818
1570
223
721
634
962
1819
NA
NA
220
222
221
723
724
975
977
976
926
922
782
783
234
501

VIRUS
AAV-DJ-CaMKIIa-eArch 3.0-eYFP
AAV-DJ-CaMKIIa-eArch 3.0-eYFP
AAV-DJ-CaMKIIa-eArch 3.0-eYFP
AAV-DJ-CaMKIIa-eArch 3.0-eYFP
AAV-DJ-CaMKIIa-eArch 3.0-eYFP
AAV-DJ-CaMKIIa-eArch 3.0-eYFP
AAV-DJ-CaMKIIa-eArch 3.0-eYFP
AAV-DJ-CaMKIIa-eArch 3.0-eYFP
AAV-DJ-CaMKIIa-eArch 3.0-eYFP
AAV-DJ-CaMKIIa-eArch 3.0-eYFP
AAV-DJ-CaMKIIa-eNpHR 3.0-eYFP
AAV-DJ-CaMKIIa-eNpHR 3.0-eYFP
AAV-DJ-CaMKIIa-eNpHR 3.0-eYFP
AAV-DJ-CaMKIIa-eNpHR 3.0-eYFP
AAV-DJ-CaMKIIa-eNpHR 3.0-eYFP
AAV-DJ-CaMKIIa-eNpHR 3.0-eYFP
AAV-DJ-CaMKIIa-eNpHR 3.0-eYFP
AAV-DJ-CaMKIIa-eNpHR 3.0-eYFP
AAV-DJ-CaMKIIa-eNpHR 3.0-eYFP
AAV-DJ-CaMKIIa-mCherry (Control)
AAV-DJ-CaMKIIa-mCherry (Control)
AAV-DJ-CaMKIIa-mCherry (Control)
AAV-DJ-CaMKIIa-mCherry (Control)
AAV-DJ-CaMKIIa-mCherry (Control)
AAV-DJ-CaMKIIa-mCherry (Control)
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IN
INJECTION
RESULTS? AREA
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
N
PPTg
N
PPTg
N
PPTg
N
PPTg
N
PPTg
N
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
Y
PPTg
N
PPTg
N
PPTg

Appendix 2: Antibody List
TYPE
Sera

ANTIBODY

SOURCE

CATALOG/LOT #s

DILUTION

Normal Donkey Serum

Millipore

S30-100ML/NG1827420

2%

Millipore
Jackson
Invitrogen

DO0176250/227040
711-065-152/92433
N21483/927003

(1:200)
(1:500)
(1:200)

Abcam
Millipore
Millipore
Jackson
Jackson
Jackson

ab13970
AB144P/2713234
41-7800/QC215902
703-545-155
705-165-147/134527
711/165-152/126883

(1:500)
(1:100)
(1:300)
(1:500)
(1:500)
(1:500)

Thermo
Fisher
Millipore
Jackson
Jackson

PA5-21397
AB144P/2713234
711-605-152
105-545-147/125100

(1:200)
(1:100)
(1:500)
(1:500)

Abcam
Millipore
Jackson
Jackson

AB205402
AB144P/2713234
703-165-155/130328
105-545-147/125100

(1:500)
(1:100)
(1:500)
(1:500)

Used for
CTB
Goat anti- CTB
1°
Biotin Donkey anti-Goat
2°
Conjugate
Streptavidin Alexa Fluor 488
Used for Archaeorhodopsin and Halorhodopsin
Chicken anti-GFP (both)
1°
Goat anti-ChAT (PPTg)
1°
Rabbit anti-VGluT2 (PnC)
1°
A488 Donkey anti-Chicken
2°
Cy3 Donkey anti-Goat (PPTg)
2°
Cy3
Donkey anti-Rabbit (PnC)
2°
Used for
AAVrg
Rabbit anti-GAD67 (PPTg)
1°
Goat anti-ChAT (PPTg)
1°
A647 Donkey anti-Rabbit (PPTg)
2°
A488 Donkey anti-Goat (PPTg)
2°
Used for CaMKII-mCherry
Chicken anti-mCherry (PPTg)
1°
Goat anti-ChAT (PPTg)
1°
Cy3 Donkey anti-Chicken (PPTg)
2°
A488 Donkey anti-Goat (PPTg)
2°
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